142 related articles for article (PubMed ID: 33881137)
1. Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Takeyasu Y; Yoshida T; Motoi N; Teishikata T; Tanaka M; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Kakishima H; Tsuchida T; Yamamoto N; Ohe Y; Yatabe Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1114-1122. PubMed ID: 33881137
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
Ariyasu R; Uchibori K; Ninomiya H; Ogusu S; Tsugitomi R; Manabe R; Sakamaoto H; Tozuka T; Yoshida H; Amino Y; Kitazono S; Yanagitani N; Takeuchi K; Nishio M
Thorac Cancer; 2021 Feb; 12(4):504-511. PubMed ID: 33350072
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
Sakaguchi T; Iketani A; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Taguchi O; Hataji O
Thorac Cancer; 2021 Feb; 12(4):462-467. PubMed ID: 33314600
[TBL] [Abstract][Full Text] [Related]
4. Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples.
Nemoto D; Yokose T; Katayama K; Murakami S; Kato T; Saito H; Suzuki M; Eriguchi D; Samejima J; Nagashima T; Ito H; Yamada K; Nakayama H; Masuda M
Thorac Cancer; 2021 Jan; 12(2):194-200. PubMed ID: 33185331
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum to: Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Takeyasu Y; Yoshida T; Motoi N; Teishikata T; Tanaka M; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Kakishima H; Tsuchida T; Yamamoto N; Ohe Y; Yatabe Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1183. PubMed ID: 34100088
[No Abstract] [Full Text] [Related]
6. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Sakata S; Otsubo K; Yoshida H; Ito K; Nakamura A; Teraoka S; Matsumoto N; Shiraishi Y; Haratani K; Tamiya M; Ikeda S; Miura S; Tanizaki J; Omori S; Yoshioka H; Hata A; Yamamoto N; Nakagawa K
Cancer Sci; 2022 Jan; 113(1):221-228. PubMed ID: 34704312
[TBL] [Abstract][Full Text] [Related]
7. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
9. Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
DiBardino DM; Saqi A; Elvin JA; Greenbowe J; Suh JH; Miller VA; Ali SM; Stoopler M; Bulman WA
Clin Lung Cancer; 2016 Nov; 17(6):517-522.e3. PubMed ID: 27378171
[TBL] [Abstract][Full Text] [Related]
10. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non-small cell lung cancer.
Sakaguchi T; Nishii Y; Iketani A; Esumi S; Esumi M; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Katsuta K; Taguchi O; Hataji O
Thorac Cancer; 2022 May; 13(10):1449-1456. PubMed ID: 35384314
[TBL] [Abstract][Full Text] [Related]
12. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
14. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
[TBL] [Abstract][Full Text] [Related]
16. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
17. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
18. Pathological criteria for multiplex gene-panel testing using next-generation sequencing in non-small cell lung cancer.
Mizote S; Matsumura M; Sekiya M; Sugiyama M; Sekine A; Kobayashi N; Kataoka T; Iwashita H; Okudela K
Cancer Treat Res Commun; 2022; 32():100614. PubMed ID: 35878517
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
20. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
